Jill Feldman, cofounder and president, EGFR Resisters, shares the importance of being proactive in managing dermatologic toxicities in epidermal growth factor receptor (EGFR)–positive lung cancer.
Jill Feldman
Advertisement
Lung cancer patient, advocate, cofounder and president of EGFR Resisters.
Articles by Jill Feldman
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
2
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
3
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
4
Efgartigimod Outperforms Standard IVIG in Averting Myasthenic Crisis
5
